There’s a specter haunting Wall Street: the Ozempic panic.
Hemsley, the former CEO of UnitedHealth Group and its current board chair, also ...
Preventive biologics can address the anti-infectives market failure while simult...
This week on the "First Opinion Podcast": an entirely new way to think about lon...
Waystar, a revenue cycle management company, filed for an IPO Monday.
Patient safety is paramount to the FDA, so stopping Cassava’s two Phase 3 studie...
Breast cancer is deadlier for Black women. A study of mammograms could help clos...
Doctors lowered the incidence of heart disease and strokes among their patients ...
Antiverse and GlobalBio have extended their collaboration agreement to advance ...
Leucine is joining the artificial intelligence (AI) wave sweeping through the p...
Vaxcyte has signed a new commercial agreement with Lonza for the global manufac...
The US Food and Drug Administration (FDA) has granted a priority review to the ...
The United States Food and Drug Administration (FDA) has approved yet another c...
Dutch biotech firm, NorthSea Therapeutics, has seen one of its treatments for n...
Spanish biotech SpliceBio has signed a licensing agreement with Spark Thera...
